DE3738721C2 - Immobilisierte Antikörper - Google Patents
Immobilisierte AntikörperInfo
- Publication number
- DE3738721C2 DE3738721C2 DE3738721A DE3738721A DE3738721C2 DE 3738721 C2 DE3738721 C2 DE 3738721C2 DE 3738721 A DE3738721 A DE 3738721A DE 3738721 A DE3738721 A DE 3738721A DE 3738721 C2 DE3738721 C2 DE 3738721C2
- Authority
- DE
- Germany
- Prior art keywords
- antibodies
- matrix polymer
- immobilized
- antibody
- bifunctional reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920000642 polymer Polymers 0.000 claims description 25
- 239000011159 matrix material Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 15
- 230000003647 oxidation Effects 0.000 claims description 15
- 238000007254 oxidation reaction Methods 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 14
- 230000001588 bifunctional effect Effects 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 125000003172 aldehyde group Chemical group 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 238000009833 condensation Methods 0.000 claims description 9
- 230000005494 condensation Effects 0.000 claims description 9
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004593 Epoxy Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 125000000837 carbohydrate group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 3
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 claims description 3
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 125000001976 hemiacetal group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000005367 Carboxypeptidases Human genes 0.000 description 10
- 108010006303 Carboxypeptidases Proteins 0.000 description 10
- 239000008351 acetate buffer Substances 0.000 description 8
- 150000001720 carbohydrates Chemical group 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 238000009010 Bradford assay Methods 0.000 description 3
- 108010015133 Galactose oxidase Proteins 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011942 biocatalyst Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- AHIBBXGQDYWLGF-UHFFFAOYSA-N 2,3-dinitrophenol 2-nitrophenol Chemical compound [N+](=O)([O-])C1=C(C=CC=C1)O.[N+](=O)([O-])C=1C(=C(C=CC1)O)[N+](=O)[O-] AHIBBXGQDYWLGF-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- KQROHCSYOGBQGJ-UHFFFAOYSA-N 5-Hydroxytryptophol Chemical compound C1=C(O)C=C2C(CCO)=CNC2=C1 KQROHCSYOGBQGJ-UHFFFAOYSA-N 0.000 description 1
- ALEBYBVYXQTORU-UHFFFAOYSA-N 6-hydrazinyl-6-oxohexanoic acid Chemical compound NNC(=O)CCCCC(O)=O ALEBYBVYXQTORU-UHFFFAOYSA-N 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- -1 amino, thio Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920005613 synthetic organic polymer Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 102000015486 thyroid-stimulating hormone receptor activity proteins Human genes 0.000 description 1
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3738721A DE3738721C2 (de) | 1987-11-14 | 1987-11-14 | Immobilisierte Antikörper |
| IL87550A IL87550A0 (en) | 1987-11-14 | 1988-08-24 | Immobilized antibodies and their production |
| NL8802236A NL8802236A (nl) | 1987-11-14 | 1988-09-12 | Geimmobiliseerde antilichamen, alsmede werkwijzen ter bereiding ervan. |
| FR888814546A FR2623193B1 (fr) | 1987-11-14 | 1988-11-08 | Anticorps immobilises, fixes par liaison covalente a un polymere-matrice, et leur procede de preparation |
| GB8826392A GB2212500B (en) | 1987-11-14 | 1988-11-11 | Immobilized antibodies |
| US07/270,280 US4948836A (en) | 1987-11-14 | 1988-11-14 | Immobilized antibodies |
| SE8804100A SE8804100L (sv) | 1987-11-14 | 1988-11-14 | Immobiliserade via sitt modifierade kolhydratomraade kovalent till en matrispolymer bundna antikroppar |
| DK635388A DK635388A (da) | 1987-11-14 | 1988-11-14 | Immobiliserede antistoffer |
| CH4207/88A CH677363A5 (enExample) | 1987-11-14 | 1988-11-14 | |
| JP63285945A JPH01165600A (ja) | 1987-11-14 | 1988-11-14 | 固定化抗体およびその製法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3738721A DE3738721C2 (de) | 1987-11-14 | 1987-11-14 | Immobilisierte Antikörper |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3738721A1 DE3738721A1 (de) | 1989-05-24 |
| DE3738721C2 true DE3738721C2 (de) | 1995-10-05 |
Family
ID=6340504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3738721A Expired - Fee Related DE3738721C2 (de) | 1987-11-14 | 1987-11-14 | Immobilisierte Antikörper |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4948836A (enExample) |
| JP (1) | JPH01165600A (enExample) |
| CH (1) | CH677363A5 (enExample) |
| DE (1) | DE3738721C2 (enExample) |
| DK (1) | DK635388A (enExample) |
| FR (1) | FR2623193B1 (enExample) |
| GB (1) | GB2212500B (enExample) |
| IL (1) | IL87550A0 (enExample) |
| NL (1) | NL8802236A (enExample) |
| SE (1) | SE8804100L (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3909456A1 (de) * | 1989-03-22 | 1990-09-27 | Roehm Gmbh | Verbessertes verfahren zur herstellung immobilisierter antikoerper |
| DE4005927A1 (de) * | 1990-02-25 | 1991-08-29 | Roehm Gmbh | Immobilisierung von proteinen an traegern |
| US5082929A (en) * | 1990-08-08 | 1992-01-21 | Bioprobe International, Inc. | Immobilization of glycocompounds and glycoconjugates |
| CA2167931A1 (en) * | 1993-08-27 | 1995-03-02 | Edward N. Granados | Hydrazine derivatized cells |
| JPH11503005A (ja) * | 1995-03-08 | 1999-03-23 | アクゾ ノーベル ナムローゼ フェンノートシャップ | 表面修飾されたアフィニティ分離膜 |
| US6509104B2 (en) | 2000-12-05 | 2003-01-21 | Michigan Biotechnology Institute | Antithrombogenic polymer coating |
| TW200307734A (en) | 2002-03-20 | 2003-12-16 | Michigan Biotech Inst | Conductive polymer-based material |
| DE102010038330A1 (de) | 2010-07-23 | 2012-03-01 | Aj Innuscreen Gmbh | Verfahren, Vorrichtung und Testkit für Molekularbiologische Reaktionen |
| TWI799441B (zh) * | 2017-08-23 | 2023-04-21 | 日商Ｊｓｒ股份有限公司 | 層析用載體﹑配位子固定載體﹑層析管柱﹑標的物質之純化方法，及層析用載體之製造方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1083508A (fr) * | 1975-11-13 | 1980-08-12 | Jacques Grange | Supports porteurs de chaines laterales, procedes d'obtention de ces supports, procedes de fixation de composes organiques comportant un residu glucidique sur lesdits supports, produits et reactifs resultant de ladite fixation chimique |
| US4210723A (en) * | 1976-07-23 | 1980-07-01 | The Dow Chemical Company | Method of coupling a protein to an epoxylated latex |
| US4208309A (en) * | 1977-05-20 | 1980-06-17 | Rohm Gmbh | Pearl polymer containing hollow pearls |
| DE3106456A1 (de) * | 1981-02-21 | 1982-10-07 | Röhm GmbH, 6100 Darmstadt | Verfahren zur herstellung von perlfoermigen, hydrophilen, gegenueber proteinen bindungsaktiven traegerpolymeren |
| JPS5853757A (ja) * | 1981-09-25 | 1983-03-30 | Denki Kagaku Kogyo Kk | 免疫アフイニテイクロマトグラフイ−用吸着体及びその製法 |
| CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
| US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4889916A (en) * | 1985-11-19 | 1989-12-26 | The Johns Hopkins University | Protein label and drug delivery system |
| US4874813A (en) * | 1987-02-09 | 1989-10-17 | Shannessy Daniel J O | Proteins bound to a marker or solid phase support matrix using a hydrazone linkage |
-
1987
- 1987-11-14 DE DE3738721A patent/DE3738721C2/de not_active Expired - Fee Related
-
1988
- 1988-08-24 IL IL87550A patent/IL87550A0/xx not_active IP Right Cessation
- 1988-09-12 NL NL8802236A patent/NL8802236A/nl not_active Application Discontinuation
- 1988-11-08 FR FR888814546A patent/FR2623193B1/fr not_active Expired - Fee Related
- 1988-11-11 GB GB8826392A patent/GB2212500B/en not_active Expired
- 1988-11-14 CH CH4207/88A patent/CH677363A5/de not_active IP Right Cessation
- 1988-11-14 US US07/270,280 patent/US4948836A/en not_active Expired - Fee Related
- 1988-11-14 JP JP63285945A patent/JPH01165600A/ja active Pending
- 1988-11-14 SE SE8804100A patent/SE8804100L/xx not_active Application Discontinuation
- 1988-11-14 DK DK635388A patent/DK635388A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL87550A0 (en) | 1989-01-31 |
| NL8802236A (nl) | 1989-06-01 |
| GB8826392D0 (en) | 1988-12-14 |
| DE3738721A1 (de) | 1989-05-24 |
| GB2212500B (en) | 1992-01-22 |
| FR2623193B1 (fr) | 1994-10-14 |
| CH677363A5 (enExample) | 1991-05-15 |
| GB2212500A (en) | 1989-07-26 |
| US4948836A (en) | 1990-08-14 |
| SE8804100L (sv) | 1989-05-15 |
| SE8804100D0 (sv) | 1988-11-14 |
| DK635388D0 (da) | 1988-11-14 |
| FR2623193A1 (fr) | 1989-05-19 |
| JPH01165600A (ja) | 1989-06-29 |
| DK635388A (da) | 1989-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2808515C2 (enExample) | ||
| DE2661112C2 (de) | Verfahren zur Herstellung eines unlöslichen Trägers | |
| DE2808476C2 (de) | Reagens zur Verwendung in immunochemischen Untersuchungsmethoden | |
| DE69429345T2 (de) | Überzug für hydrophobe oberflächen um diese proteinresistent zu machen unter ermöglichung der kovalenten bindung spezifischer liganden | |
| EP0491362B1 (de) | Verwendung von Peptidpaaren mit extrem hoher spezifischer Affinität zueinander im Bereich der in vitro Diagnostik | |
| DE2430357C2 (de) | Verfahren zur qualitativen oder quantitativen Feststellung von Immunoglobulin der IgG-Klasse | |
| DE3105768C2 (de) | Verwendung eines Trägers für die Immobilisierung von bioaktiven Materialien | |
| US4218539A (en) | Enzyme conjugates and method of preparation and use | |
| DE2155658C3 (de) | Verfahren zum Nachweis und zur Bestimmung von einem Hapten oder dessen Antikörper | |
| DE69132055T2 (de) | Ortsgenaue konjugatbildung zwischen immunglobulinen und nachweisbaren markierungsstoffen | |
| EP0484472B1 (de) | Verfahren zur lichtinduzierten immobilisierung von biomolekülen an chemisch "inerten" oberflächen | |
| WO1995023801A1 (de) | Entstörmittel zum einsatz bei immunoassays | |
| EP0397113A2 (de) | Verfahren zum Nachweis spezifisch bindefähiger Substanzen in Körperflüssigkeiten | |
| DE68919828T2 (de) | Nanoteilchen mit gebundenen enzym und ligand zur verwendung bei analysen. | |
| DE2552510C3 (de) | Biologisch aktive Verbindungen und Verfahren zu ihrer Herstellung | |
| DE3738721C2 (de) | Immobilisierte Antikörper | |
| EP0749435A1 (de) | Entstörmittel zum einsatz bei immunoassays | |
| DE3909456A1 (de) | Verbessertes verfahren zur herstellung immobilisierter antikoerper | |
| DE4240056A1 (de) | Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper | |
| DE3485839T2 (de) | Fluorometrische pruefung des gesamten ige niveaus und reagens dafuer. | |
| DE3224217A1 (de) | Enzymimmunoassay-methode zur qualitativen und quantitativen bestimmung von substanzen | |
| DE69822446T2 (de) | Cyclosporin derivate und deren verwendung | |
| EP0322813A2 (de) | Verfahren zur Bestimmung einer immunologisch aktiven Substanz | |
| US4360592A (en) | Process for the detection of antibodies | |
| DE2061009A1 (de) | Verfahren zur Fixierung von Polymeren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |